

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070170 A2

(51) International Patent Classification⁷:

A61K

(21) International Application Number: PCT/US03/04426

(22) International Filing Date: 13 February 2003 (13.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/357,554 15 February 2002 (15.02.2002) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FAVREAU, Denis [CA/CA]; 5065 Terrasse Beaudry, St. Hubert, Québec 00000 (CA). KANT, Joydeep [US/US]; 221 Hadleigh Drive, Cherry Hill, NJ 08003 (US). LEVESQUE, Kathia [CA/CA]; 585 rue Leveillée, St-Catherine, Québec J0L 1EO (CA). WANG, Shaopeng [CN/US]; 2745 Langley Circle, Glenview, IL 60025 (US). GUO, Zhengrong [US/US]; 21 Augusta Place, East Brunswick, NJ 08816 (US). JAMES, Brian, L. [US/US]; 7257 Leafcrest Lane, East Syracuse, NY 13057 (US).



(74) Agents: BAXAM, Deanna et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/070170 A2

(54) Title: METHOD OF PREPARATION OF 21-AMINO EPOTHILONE DERIVATIVES

(57) Abstract: An improved method of synthesis of 21-amino epothilone derivatives which provides a one-pot conversion of 21-hydroxy epothilones to highly desirable 21-amino epothilones in high yield.

Method of Preparation of 21-Amino Epothilone Derivatives

This application claims a benefit of priority from U.S. Provisional Application No. 60/357,554, the entire disclosure of which is herein
5 incorporated by reference.

FIELD OF THE INVENTION


The invention relates to the fields of organic synthesis, pharmaceutical
10 process chemistry, and cancer chemotherapy. In particular, the inventive concept relates to an improved method of preparing 21-amino epothilone derivatives, which are useful in the treatment of a broad spectrum of tumors, including taxol-resistant tumors.

15

BACKGROUND OF THE INVENTION

Epothilones are macrocyclic lactones with useful antifungal and cytotoxic properties. Their action, as is the case with paclitaxel, is based on stabilization of microtubules, causing mitotic arrest in rapidly dividing cells and
20 thus inhibition of the growth of tumors. For reviews, see E. Nogales, *Ann. Rev. Biochem.*, 2000, 69:277-302; L. Wessjohann, *Angew. Chem. Int. Ed. Engl.* 1997, 36:715-718; Höfle et al., *Angew. Chem. Int. Ed. Engl.*, 1996, 35:1567-1569; and K.C. Nicolaou et al., *Angew. Chem. Intl. Ed. Engl.*, 1998,

37:2014-2045. Typical epothilones, for example epothilones A, B, C, and D, carry a methylthiazolyl side chain, as shown below.



Epothilone A: R = H
Epothilone B: R = CH₃

Epothilone C: R = H
Epothilone D: R = CH₃

Synthetic and semi-synthetic derivatives and analogues of epothilones have
5 been described, in which carbon atoms 12 and 13 are variously derivatized
via modification of the double bond or epoxide present in epothilones A, B, C,
and D. Examples are found in U.S. Patent No. 6,399,638, issued June 4,
2002, which is commonly assigned with the present application and whose
entire disclosure is incorporated herein by reference.

10

Functionalization of the C-21 position of epothilones has been
accomplished via rearrangement of thiazole N-oxides, as described by G.
Höfle et al., *Angew. Chem. Int. Ed.*, 1999, 38:1971-1974; and also in PCT
international patent applications WO 98/22461 and WO 98/38192 (which are
15 incorporated herein by reference). Alternatively, 21-hydroxy epothilones may
be obtained by biotransformation (21-hydroxylation) of epothilones A-D with
the aid of, for example, *Sorangium cellulosum* strains as described in WO
98/22461, or by *Actinomycetes* sp., e.g. strain SC15847 as described in WO
00/39276. The conversion of 21-hydroxy to 21-amino epothilones has been
20 described by Höfle et al. in German patent applications DE 199 07 588 and

DE 199 30 111, and in PCT international application WO 00/50423. These prior art methods utilize at least two steps, in contrast to the presently claimed invention.

5 The 21-amino epothilones and their derivatives are promising anti-tumor agents, however there are recognized difficulties associated with their production on a manufacturing scale. Because of the complexity of epothilone-like structures, advanced chemical intermediates must be prepared either by fermentation methods or by lengthy total syntheses, and
10 these intermediates are accordingly expensive to produce. There remains a need, therefore, for shorter and higher-yielding processes for the preparation of 21-amino epothilones from such intermediates.

BRIEF DESCRIPTION OF THE INVENTION


15 The invention provides improved methods for synthesis of 21-amino epothilone derivatives, in which the prior art (DE 199 07 588, DE 199 30 111 and WO 00/50423) two-step conversion of a 21-hydroxy epothilone to a 21-amino epothilone is replaced by a one-pot process. The process generally
20 comprises contacting a 21-hydroxy epothilone with an azide transfer agent and a suitable base, under conditions conducive to formation of the 21-azido epothilone, and conversion of the 21-azido group to a 21-amino group by reaction *in situ* with a reducing agent, followed by hydrolysis. The improved

methods of the invention provide for a higher yield of 21-amino epothilones, and a considerable savings in time and cost of the conversion.

DETAILED DESCRIPTION OF THE INVENTION


5

The invention provides methods for the preparation of 21-amino epothilone derivatives of general formula (I):



In formula (I), R is selected from the group consisting of H, alkyl, or
 10 substituted alkyl; X is selected from the group consisting of a carbon-carbon bond (as in epothilones C and D), O, S, CH₂, or NR'; Y is O or NH; R' is selected from the group consisting of H, alkyl, aryl, -CO-R'', -CO₂R'', CONHR'', CONR''R'', -SO₂R'', SO₂NHR'', and SO₂NR''R''. R'' and R''' are independently selected from the group consisting of alkyl, aryl, aryl-alkyl, heteroaryl, and heteroaryl-alkyl, or R'' and R''' taken together with the nitrogen to which they are attached may comprise a nitrogen heterocycle, and additionally R'' may be H. Where X is a carbon-carbon bond, the 12,13-olefin may be of *E* or *Z* stereochemistry.

15 The preparation of the compounds of formula (I) may be carried out according to Scheme 1.

Scheme 1


Starting from epothilones A-D, or from synthetic or semisynthetic derivatives thereof, shown in Scheme 1 as formula (II), epothilone N-oxides of formula (III) can be obtained as described in the references cited above then converted to 21-OH epothilones of formula (IV). The epothilone starting material may optionally be purified by conventional means, for example by crystallization and/or chromatography, to minimize the proportion of impurities before being reacted to form the N-oxide.

10

One or both the 3-hydroxyl and 7-hydroxyl groups of the compound of formula (III) may optionally be protected, for example with trimethylsilyl groups or other trialkyl silyl groups, during formation of the N-oxide. Those skilled in

the art will appreciate that it may also be advantageous or necessary to protect reactive functional groups in the moiety X, as appropriate (see, for example, WO 97/19086, the entire disclosure of which is herein incorporated by reference). Any other protecting means known in the art may also be
5 employed for this purpose.

The N-oxide (formula III) is reacted with an acyl anhydride, preferably trifluoroacetic anhydride, in the presence of a hindered base such as collidine or 2,6-lutidine, to yield the 21-hydroxy epothilones IV after hydrolysis.

Scheme 2

An exemplary process for preparing 21-amino epothilones via an N-oxide obtained from epothilone B is shown in the first two reaction steps of Scheme 2. The N-oxide of epothilone B, 2, is reacted to form epothilone F, 3, which is the starting material converted to an azido derivative, 4. The azido derivative 5 is then reduced to form the 21-amino epothilone derivative, 5.

Generally, as shown in Scheme 1, the 21-hydroxy epothilones of formula (IV) may be obtained by oxidizing, then further reacting an epothilone starting material, which can be selected from epothilones A-D. Alternatively, 10 the 21-hydroxy epothilones may be obtained by biotransformation (21-hydroxylation) of epothilones, e.g. epothilones A-D, with the aid of suitable microorganisms or with enzymes. Suitable microorganisms include, for example, *Sorangium cellulosum* strains as described in PCT Patent Application WO 98/22461, and *Actinomycetes* sp., e.g. strain SC 15847, as 15 described in PCT Patent Application WO 00/39276. The entire disclosure of each of these applications is herein incorporated by reference in its entirety. Protected or unprotected epothilones such as those described in PCT Patent Application WO 97/19086) are appropriate and may be employed as the starting material in the method of the present invention. Synthetic or semi- 20 synthetic epothilone starting materials may also be used.

In the presently claimed process, the conversion of a 21-hydroxy epothilone is accomplished, for example, using a phosphoryl azide, in the presence of a suitable base under conditions conducive to formation of the

21-azido epothilone. For examples of the use of phosphoryl azides in this manner, see: G. Zuccarello et al., *J. Org. Chem.* 1998, 63:4898; G. Gosselin et al., *Nucleosides Nucleotides* 1998, 17:1731; K.C. Nicolaou et al., *Angew. Chem., Int. Ed. Engl.* 1998, 37:2708; T. Honda et al., *Heterocycles* 1996, 5 42:109; A.G. Schultz, H.A. Holoboski, M.S. Smyth, *J. Am. Chem. Soc.* 1996, 118:6210; and W.H. Pearson, J.V. Hines, *J. Org. Chem.* 1989, 54:4235.

Preferred phosphoryl azides are diaryl phosphoryl azides, and most preferred is diphenylphosphoryl azide. Any sufficiently polar and suitably inert organic solvent may be employed. The preferred solvent is tetrahydrofuran (THF).

10 The presence of water or hydroxylic impurities in the solvent may consume a portion of the phosphoryl azide reagent; this may be overcome by addition of a compensating additional amount of phosphoryl azide and base. Most preferably the solvent is THF that is substantially free of water, for example commercial "anhydrous" grade THF or THF that has been dried over

15 molecular sieves.

Suitable bases are strong hindered non-nucleophilic bases, such as for example 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU), 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), 2,4,6-tri-tert-butylpyrimidine (TTBP), and diisopropylethylamine (DIPEA). Of such bases, DBU and DBN are preferred, and DBU is most preferred. In a preferred embodiment of the invention, the base is used in an excess amount relative to the molar equivalents of phosphoryl azide.

The 21-azido epothilone is then reacted with a reducing agent, followed by treatment with water, base or buffer to provide the 21-amino derivative. It is presumed that the conversion may proceed through an intermediate. In this respect, a strong reducing agent, for example a

5 palladium catalyst such as Lindlar's catalyst, or an organophosphine reagent may be used. For example, this step may be performed by contacting the 21-azido epothilone of formula (V) with a trisubstituted phosphine. Suitable phosphines include trialkyl phosphines such as trimethyl phosphine, triethyl phosphine and tributyl phosphine; and triaryl phosphines such as triphenyl phosphine. Trimethyl phosphine is preferred.

10

Either of the foregoing alternative reducing steps may be performed without separation of the 21-azido compound from the reaction mixture obtained in the first step. Optionally, the solvent used in the azide formation

15 may be removed, for example by evaporation, and replaced in part or entirely by a second solvent, but preferably the phosphine is added directly to the reaction mixture obtained in the azide formation step.

In an alternative embodiment of the invention, the base is added

20 before the phosphine. This reverse addition may also be performed *in situ*. It should therefore be understood that within the scope of the present invention the order of addition of the phosphine reducing agent and the base may be reversed, with either variation of the process producing the desired compound of formula (I) in good yield.

As is reflected in Scheme 1, the process is completed by hydrolysis in conjunction with the reduction step. The hydrolysis may be effected by one of several means; for example by reaction with water, preferably in the presence of added acid or alkali, to obtain a 21-amino substituted compound of formula

5 (I). In this embodiment, the hydrolysis is carried out with added alkali, the most preferred alkali being aqueous ammonium salts. A buffer may also be used instead of or in addition to the base. In particular, it has been observed that addition of the buffer further reduces impurities in the reaction end product. Suitable bases or buffers include, for example, NH₄OH, NH₄Cl,

10 NH₄Br, CF₃CO₂NH₄, NH₄OAc, and mixtures thereof, e.g. aq. NH₄OH/NH₄Cl.

The process steps of the invention may be carried out at temperatures ranging from about 0°C up to the boiling point of the solvent. They are preferably carried out between about 0°C and about 40°C, and most 15 preferably between about 20°C and about 40°C.

Purification of the product preferably is achieved via chromatography and/or crystallization, though any suitable means of purification known in the art may also be used. Preferred crystallization solvents are mixtures of a 20 polar solvent and a hydrocarbon, most preferably a mixture of ethyl acetate and heptane. The crude product is typically suspended in the solvent and mixed, if necessary with heating, before cooling. Optionally, the solution may be seeded during cooling to promote crystal formation.

The synthesis of the invention may be carried out as a batch or continuous process.

The following examples are provided to illustrate the present invention.

- 5 However, it should be understood that the present invention is not limited to the examples herein described.

Conversion of (Epothilone B) to (Epothilone F)Example 1

5 Epothilone B (1.98 g, 3.90 mmol) was placed under argon and dissolved in 60 ml dry CH_2Cl_2 . To this solution was added mCPBA (0.720g, 4.17 mmol, 1.07 equivalents). The mixture was stirred at 25°C for 5.5 hours. The reaction mixture was quenched with NaHCO_3 (60 ml), and extracted with CHCl_3 (3x75 ml). The organic phase was washed with water (100 ml) followed by 5% Na_2SO_3 (aq., 70 ml) and then brine (70 ml). The organic phase was then dried over Na_2SO_4 . The crude reaction product was chromatographed using silica gel and eluted with 2% MeOH in CHCl_3 to yield the N-oxide (0.976 g, 48% yield) as a white solid.

10 followed by 5% Na_2SO_3 (aq., 70 ml) and then brine (70 ml). The organic phase was then dried over Na_2SO_4 . The crude reaction product was chromatographed using silica gel and eluted with 2% MeOH in CHCl_3 to yield the N-oxide (0.976 g, 48% yield) as a white solid.

15 (ii) To a resealable tube under argon was added the N-oxide (0.976 g, 1.86 mmol) dissolved in dry CH_2Cl_2 (35 ml), 2,6-lutidine (1.73 ml, 14.88 mmol, 8 equivalents) and $(\text{CF}_3\text{CO})_2\text{O}$ (1.84 ml, 13.02 mmol, 7 equivalents). The tube was sealed and heated at 70°C for 25 min. The mixture was allowed to cool and the solvent was removed under a stream of argon, followed by concentration to a few ml of dark yellow solution under vacuum. The reaction was diluted with MeOH (25 ml) and 28% NH_4OH (aq., 2.9 ml) was added. The mixture was heated to 45°C for 20 min, then cooled to room temperature. The crude product was concentrated on a rotary evaporator and chromatographed using silica gel, eluting with 4% MeOH in CHCl_3 to afford epothilone F (0.815 g, 84% yield).

20 concentration to a few ml of dark yellow solution under vacuum. The reaction was diluted with MeOH (25 ml) and 28% NH_4OH (aq., 2.9 ml) was added. The mixture was heated to 45°C for 20 min, then cooled to room temperature. The crude product was concentrated on a rotary evaporator and chromatographed using silica gel, eluting with 4% MeOH in CHCl_3 to afford epothilone F (0.815 g, 84% yield).

25 epothilone F (0.815 g, 84% yield).

Example 2


Epothilone B (5.08 g, 10.0 mmol) was placed under argon and dissolved in dry CH_2Cl_2 (150 ml). To this solution was added powdered 5 NaHCO_3 (2.11 g, 25.0 mmol, 2.5 equivalents) and purified mCPBA (4.31 g, 25.0 mmol, 2.5 equivalents). The mixture was stirred at 25°C for 6 hours. The reaction mixture was washed with water (100 ml) followed by 5% Na_2SO_3 (aq., 70 ml) and then brine (70 ml), and the organic phase was dried over Na_2SO_4 . The crude reaction product was chromatographed on silica gel, 10 eluting with 20-30% $\text{EtOAc} / 2\% \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$, to afford the N-oxide (1.93 g., 36.8% yield) as a white fluffy solid. Larger-scale runs, employing 15 and 19 g of starting material, provided N-oxide epothilone B in yields of 39 and 32%, respectively.

15 The N-oxide (1.89 g, 3.60 mmol) was dissolved in dry CH_2Cl_2 (100 ml), 2,6-lutidine (3.15 ml, 27 mmol, 7.5 equivalents) and $(\text{CF}_3\text{CO})_2\text{O}$ (1.78 ml, 12.6 mmol, 3.5 equivalents). The mixture was stirred at 25°C for 3 hours, then diluted with EtOH (60 ml), and the CH_2Cl_2 was removed under vacuum. The residue was cooled to 0°C, and 28% aqueous NH_4OH (0.73 ml, 6 equivalents) was added. The mixture was stirred at 0°C for 2 hours, and then 20 concentrated on a rotary evaporator and chromatographed on silica gel and eluted with 2% $\text{MeOH} / 0.2\% \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$ to afford of epothilone F (0.95 g, 50% yield). Larger-scale runs, employing 6 and 6.42 g of starting material, also provided epothilone F in yields of 50%, with an additional 2 g of 25 epothilone F present in mixed chromatographic fractions.

Comparative Examples – Multi-Step SynthesisExample 3

Preparation and Isolation of

5 [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Azidomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione.



10 To a stirred solution of epothilone F (957 mg, 1.83 mmol) in tetrahydrofuran (20 ml) at 0°C under argon was added diphenylphosphoryl azide (0.47 ml, 604 mg, 2.19 mmol, 1.2 equivalents). (Epothilone F can, for example, be obtained according to the process described in commonly assigned and co-pending U.S. Patent Application No. 09/468,854, the entire disclosure of which is incorporated herein by reference). The mixture was stirred for approximately 3 min. 1,8-diazabicyclo [5.4.0]undec-7-ene (0.27 ml, 278 mg, 1.83 mmol, 1 equivalents) was then added and the mixture was stirred at 0°C. After 2 hours, the mixture was warmed to 25°C and stirred for 20 hours. The reaction mixture was diluted with ethyl acetate (150 ml) and 15 washed with H₂O (50 ml). The aqueous layer was extracted with ethyl acetate (35 ml), and the combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The crude material was chromatographed using 20

silica gel eluted with 50% ethyl acetate in hexanes to afford 21-azido-epothilone B (913 mg, 91% yield) as a clear, colorless oil. MS (ESI+): 549.3 (M+H)+; ¹H-NMR (300 MHz, CDCl₃); δ = 6.59 (bs, 17-H), 7.04 (s, 19-H), 4.63 (s, 21-H₂); HRMS (DCI); C₂₇H₄₀N₄O₆S: [M+] calculated 549.2747, found 5 549.2768.

Example 4

Preparation and Isolation of 10 [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-3-[2-[2-(Azidomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

To a stirred solution of epothilone F (5 g, 9.55 mmol) in tetrahydrofuran (40.0 ml) at room temperature was added diphenylphosphoryl azide (2.28 ml, 15 2.89 g, 10.5 mmol, 1.1 equivalents). The mixture was stirred for approximately 5 min. 1,8-Diazabicyclo [5.4.0]undec-7-ene (1.72 ml, 1.74 g, 11.46 mmol, 1.2 equivalents) was then added. The mixture was heated to 40 °C and stirred for 3 hours. The reaction mixture was cooled to room 20 temperature and diluted with ethyl acetate (160 ml), followed by washing with H₂O (25 ml). The organic layer was washed with 10% aqueous NH₄OH (25 ml), followed by 1M NH₄OH (25 ml). The combined aqueous layers were extracted with EtOAc (20 ml). The combined organic layers were washed with 15% aqueous NaH₂PO₄ (20 ml), dried over Na₂SO₄, and concentrated under vacuum to afford 21-azido-epothilone B (5.0 g. 95.4% yield) as a white 25 solid.

Example 5**Conversion to**

[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-
5 4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

To a stirred solution of 21-azido-epothilone B (1.0 g, 1.82 mmol) in tetrahydrofuran (10.0 ml) was added trimethylphosphine (1 M in THF, 1.91 ml, 1.91 mmol, 1.05 equivalents) at room temperature. The mixture was stirred 10 for 15 min. An aqueous solution of NH₄OH (1M, 1 ml) was added at room temperature. After the mixture was stirred at room temperature for 30 min, EtOAc (50 ml) and H₂O (10 ml) were added. The organic layer was washed with 5% aqueous NaH₂PO₄ (10 ml) and H₂O (10 ml). The organic phase was then dried over MgSO₄ and the solvents were removed under vacuum to yield 15 21-amino epothilone B (0.81 g, 85% yield) as a slightly pink solid.

Preparation of 21-Amino Epothilone Derivatives**Example 6**

20 **Synthesis of**
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-
4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

25 To a stirred suspension of epothilone F (10 g, 19.1 mmol) in tetrahydrofuran (200 ml) under argon, chilled in an ice bath to 5°C or below,

was added diphenylphosphoryl azide (6.20 ml, 7.90 g, 28.6 mmol, 1.5 equivalents). The mixture was stirred for approximately 10 min. 1,8-diazabicyclo[5.4.0]undec-7-ene (3.43 ml, 3.53 g, 22.8 mmol, 1.2 equivalents) was then added gradually at a rate that maintained the temperature of the 5 mixture below 8°C. The mixture was stirred for 30 min., then allowed to warm to 20°C and stirred for 18 hours. To the reaction mixture was added a solution of 1.0 M trimethylphosphine in tetrahydrofuran (21 ml, 18.3 g, 21 mmol, 1.1 equivalents), which generated a mild exotherm with gas evolution. The mixture was allowed to stir at 20°C for 30 minutes, and water 10 (52 ml) was added. After 30 minutes, 28% aqueous NH₄OH (26.5 ml) was added. After stirring at 25°C for another 30 minutes, water (100 ml) was added, and the mixture was extracted with methylene chloride (3 x 100 ml). The combined organic extracts were washed with 1.0 M aqueous ammonium hydroxide (2 x 100 ml), and then with half-saturated aqueous sodium chloride 15 (100 ml). The solvents were removed on a rotary evaporator, and the residue dried *in vacuo* for 18 hours.

The crude material from several synthetic runs (from 36 g starting material in total) was chromatographed on silica gel (810 g, density 0.45 g/ml; 20 1800 ml), and eluted with 0.2% Et₃N, 2.5% MeOH in CH₂Cl₂, to yield 21-amino epothilone B (27.1 g) as a white solid. MS (ESI+): 523.3 (M+H)⁺. An additional 2.37 g was obtained by re-chromatography of later mixed fractions, for a total of 29.5 g (82.4% yield).

The material was dissolved in CH₂Cl₂, (200 ml) and the solution filtered through a 0.45 micron membrane (DuraporeTM HVHP, Millipore Inc., Bedford MA) and evaporated to dryness *in vacuo*. Crystallization was carried out by dissolving the residue in ethyl acetate (344 ml) at 75°C, slowly adding 5 cyclohexane (688 ml), and slowly cooling with stirring and with addition of seed crystals of 21-amino epothilone B. The mixture was held with stirring at 40°C for an hour, then allowed to cool further to room temperature and stirred for 12 hours. The mixture was then cooled to below 5°C in an ice bath, stirred for 4 hours at 0 to 5°C, and filtered. The solids were rinsed with ice-cold 10% 10 ethyl acetate in cyclohexane (3 x 30 ml) and then dried *in vacuo* at 40°C for 18 hours to provide crystalline 21-amino epothilone B (27 g, 75% overall yield) as white plates.

15

Example 7

Synthesis of [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

20 THF was dried over 3A molecular sieves prior to use. To a stirred suspension of epothilone F (10 g, 19.1 mmol) in dry tetrahydrofuran (200 ml) under argon, was added diphenylphosphoryl azide (6.20 ml, 7.90 g, 28.6 mmol, 1.5 equivalents). The mixture was stirred for about 10 min. 1,8-diazabicyclo[5.4.0]undec-7-ene (3.43 ml, 3.53 g, 22.8 mmol, 1.2 equivalents) 25 was added gradually, at a rate that maintained the temperature of the mixture

below 30°C. The mixture was stirred for 12 to 24 hours (overnight). To the reaction mixture was added a solution of 1.0 M trimethylphosphine in tetrahydrofuran (21 ml, 18.3 g, 21.04 mmol, 1.1 equivalents), at a rate that maintained the temperature of the mixture below 27°C. The mixture was 5 stirred at room temperature for 30 minutes, and water (52 ml) was added. After 30 minutes, 28% aqueous NH₄OH (26.5 ml) was added, and the mixture stirred for 30 minutes. Water (100 ml) was added, and the mixture was extracted with methylene chloride (3 x 100 ml). The combined organic extracts were washed with 1.0M aqueous ammonium hydroxide (2 x 100 ml). 10 NMR analysis was used to determine the presence of residual diphenylphosphate in the organic phase, and an additional wash with 1.0 M aqueous ammonium hydroxide (100 ml) was carried out. The organic phase was then washed with half-saturated aqueous sodium chloride (100 ml), the solvents were removed on a rotary evaporator, and the residual solid was 15 dried *in vacuo* for 18 hours. The crude product was purified within 24 hours, or stored at -15°C or below.

The crude material was purified by chromatography and recrystallization as described in Example 6.

20

Example 8

Synthesis of [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

25

To a stirred suspension of epothilone F (47.12 g, 90.0 mmol) in tetrahydrofuran (942 ml, previously dried over 3A molecular sieves) under argon, was added diphenylphosphoryl azide (29.2 ml, 37.3 g, 135.5 mmol, 1.5 equivalents). The mixture was stirred for about 10 min. 1,8-5 diazabicyclo[5.4.0]undec-7-ene (24.5 ml, 24.94 g, 163.8 mmol, 1.8 equivalents) was then added gradually, at a rate that maintained the temperature of the mixture below 30°C. The mixture was stirred for 22 hours. To the reaction mixture was added a solution of trimethylphosphine in tetrahydrofuran (1.0 M, 99.0 ml, 86.3 g, 99.0 mmol, 1.1 equivalents), at a rate 10 that maintained the temperature of the mixture below 30°C. The mixture was stirred at room temperature for 30 minutes, and water (244 ml) was added. After 30 minutes, 28% aqueous NH₄OH (125.0 ml) was added, and the mixture stirred for 30 minutes. Water (470 ml) was added, and the mixture was extracted with methylene chloride (3 x 100 ml). The combined organic 15 extracts were washed with aqueous ammonium hydroxide (1.0 M, 3 x 470 ml). NMR analysis was used to determine the presence of residual diphenylphosphate in the organic phase. The organic phase was then washed with half-saturated aqueous sodium chloride (470 ml), the solvents were removed on a rotary evaporator, and the residual solid was dried *in* 20 *vacuo* for 18 hours to afford the crude product (56.72 g, 120.6 % yield).

The crude product was purified by column chromatography using silica gel pre-treated with 2.5% methanol - 0.2% triethylamine - dichloromethane. The chromatographed material was dissolved in CH₂Cl₂, and the solution

filtered through a 0.45 micron membrane (DuraporeTM HVHP, Millipore Inc., Bedford MA) and evaporated to dryness. To the purified product (30.6 g) was added ethyl acetate (370 mL), the resulting suspension was heated at 72-75°C to obtain a solution and n-heptane (370 mL) added slowly. The mixture 5 was treated with seeds (622 mg) and then held with stirring at 72°C for 1 hr. The suspension is then allowed to cool slowly and stirred at 15-25°C for 18 hrs. After cooling at +5°C, the resulting solid was isolated by filtration, washed with 10% ethyl acetate in heptane (93 mL in three portions) followed by vacuum drying at 50-60°C to afford the crystalline 21-amino epothilone 10 (28.93 g, 67.6% yield corrected for input potency).

Example 9

[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-15 4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione

To a suspension of epothilone F (334 g, 637.8 mmol) and diphenylphosphoryl azide (208 ml, 264.3 g, 960 mmol, 1.5 eq) in tetrahydrofuran (6680 ml, previously dried over 3A molecular sieves) was 20 added gradually 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 172 ml, 175 g, 1.15 mol, 1.8 eq) and the reaction subsequently stirred at 15-25°C for 6-18 hrs. To the reaction mixture was then added a 2.4M solution of ammonium hydroxide (2600 ml, 10 eq), followed by slow addition of a 1.0 M trimethylphosphine/tetrahydrofuran solution (700 ml, 1.1 eq), and the mixture

stirred for 1 hr. The reaction mixture was diluted with water (3340 ml) and the aqueous phase extracted with dichloromethane (3 X 3340 ml). The organic phase was then washed with diluted ammonium hydroxide (10,710 ml in five portions) and half saturated sodium chloride solutions (3340 ml in two portions); the dichloromethane solution was partially concentrated under reduced pressure to ca 1670 ml. Ethyl acetate (3340 ml) was then added and the mixture reconcentrated to 1670 ml. The process was repeated and to the mixture was added n-heptane (5010 ml). The resulting suspension was stirred for 1hr and the solid isolated by filtration followed by vacuum drying at 5 50-60C to afford the crude product (305.2 g, 91.4 % yield).

10

The crude product from two reactions (136.0 and 334.0 g input) was purified by column chromatography using silica gel pre-treated with 2.5% methanol - 0.2% triethylamine - dichloromethane, or optionally with 5% 15 methanol - ethyl acetate. The chromatographed material (340 g) was dissolved in CH_2Cl_2 , and the solution filtered through a 0.45 micron membrane (DuraporeTM HVHP, Millipore Inc., Bedford MA) and evaporated to dryness. To the purified product (339.10 g) was added ethyl acetate (4070 ml), the resulting suspension was heated at 72-75°C to obtain a solution and n- 20 heptane (4070 ml) added slowly. The mixture was allowed to cool slowly in the presence of seeds and stirred at 15-25°C. After cooling at +5°C, the resulting solid was isolated by filtration, washed with of heptane (1020 ml in three portions) followed by vacuum drying to afford crystalline 21-amino epothilone (317.7 g, 73.4% yield corrected for input potency). (Optionally, the

product can also be recrystallized from ethyl acetate - heptane to improve quality.)

Example 10

5

Synthesis of

[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione

10 To a stirred suspension of epothilone F (2.5 g, 4.77 mmol, 86.2% potency) in tetrahydrofuran (25 ml) was added diphenylphosphoryl azide (1.14 ml, 1.45 g, 5.25 mmol, 1.1 equivalents) at room temperature. The mixture was stirred for approximately 5 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.86 ml, 0.87 g, 5.73 mmol, 1.2 equivalents) was then added over 10 min.

15 The mixture was stirred for 10 min, and then allowed to warm to 40°C and stirred for 3 hours. The mixture was cooled to 30 °C, and a mixture of aqueous solution of NH₄Cl (2M, 2.5 ml) and NH₄OH (2M, 2.5 ml) was added. After the mixture was stirred for 10 min at 30 °C, trimethylphosphine (1M in tetrahydrofuran, 5.01 ml, 5.01 mmol, 1.05 equivalents) was added over 10 min. The mixture was allowed to stir at 30°C for 3 hours and then at room temperature for 15 hours. EtOAc (100 ml) and aqueous NH₄OH (1 M, 20 ml) were added. The organic layer was washed with aqueous NH₄OH (1 M, 20 ml). The combined aqueous layers were extracted with EtOAc (20 ml). The combined organic layers were washed with H₂O (20 ml) and dried over

20 MgSO₄. The solvents were removed on a rotary evaporator, and the residue

25

dried *in vacuo* to provide the crude 21-amino epothilone B (2.45 g) as an off-white solid. The crude 21-amino epothilone B (2.45 g) was crystallized from EtOAc/heptane to give 21-amino epothilone B (1.86 g, 86.5% yield corrected for input potency) as a white solid.

5

Example 11

[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione

10

To a stirred suspension of epothilone F (2.5 g, 4.77 mmol, 86.2% potency) in tetrahydrofuran (25 ml) was added diphenylphosphoryl azide (1.14 ml, 1.45 g, 5.25 mmol, 1.1 equivalents) at room temperature. The mixture was stirred for approximately 5 min. 1,8-diazabicyclo[5.4.0]undec-7-ene (0.86 ml, 0.87 g, 5.73 mmol, 1.2 equivalents) was then added over 10 min. The mixture was stirred for 10 min. and then allowed to warm to 35°C and stirred for 6.5 hours. The mixture was cooled to 10 °C, and a mixture of aqueous solution of NH₄Br (2M, 5 ml) and NH₄OH (2M, 5 ml) was added. After the mixture was stirred for 5 min, trimethylphosphine (1M in tetrahydrofuran, 5.01 ml, 5.01 mmol, 1.05 equivalents) was added over 10 min at 10 °C. The mixture was allowed to stir at 35°C for 4 hours and then cooled to room temperature. EtOAc (80 ml) and aqueous NH₄OH (1 M, 10 ml) were added. The organic layer was washed with aqueous NH₄OH (1 M, 20 ml). The combined aqueous layers were extracted with EtOAc (20 ml). The combined organic layers were washed with H₂O (20 ml) and dried over MgSO₄. The

solvents were removed on a rotary evaporator, and the residue dried *in vacuo* to provide the crude 21-amino epothilone B (2.5 g) as an off-white solid. The crude 21-amino epothilone B (2.45 g) was crystallized from EtOAc/heptane to give 21-amino epothilone B (1.95 g, 90% yield corrected for input potency) as 5 a white solid.

Example 12

10 **Synthesis of [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione**

To a stirred suspension of epothilone F (5.0 g, 9.55 mmol, 86.2% potency) in tetrahydrofuran (50 ml) was added diphenylphosphoryl azide (2.28 ml, 2.89 g, 10.5 mmol, 1.1 equivalents) at room temperature. 1,8-15 Diazabicyclo[5.4.0]undec-7-ene (1.73 ml, 1.74 g, 11.46 mmol, 1.2 equivalents) was then added over 10 min. The mixture was stirred for 10 min. and then allowed to warm to 35°C and stirred for 6.5 hours. The mixture was cooled to 20 °C, and a mixture of aqueous solution of CF₃COONH₄ (4M, 10 ml) and NH₄OH (4M, 10 ml) was added. After the mixture was stirred for 5 20 min, trimethylphosphine (1M in tetrahydrofuran, 10.03 ml, 10.03 mmol, 1.05 equivalents) was added over 10 min at 20 °C. The mixture was allowed to stir at 35 °C for 2 hours and then at 5 °C for 14 hours. EtOAc (200 ml) and aqueous NH₄OH (1 M, 10 ml) were added. The organic layer was washed with aqueous NH₄OH (1 M, 30 ml). The combined aqueous layers were 25 extracted with EtOAc (2 x 30 ml). The combined organic layers were washed

with a mixture of brine (20 ml) and H₂O (20 ml). The solvents were removed to yield ~60 ml on a rotary evaporator, and EtOAc (60 ml) was added. The solvent was removed again to ~65 ml, and the resulting slurry was crystallized from EtOAc/heptane to give 21-amino epothilone B (3.75 g, 87% yield
5 corrected for input potency) as a white solid.

Example 13

Synthesis of [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(Aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-10 pentamethyl-4,17-dioxabicyclo[4.1.0]heptadecane-5,9-dione

To a suspension of epothilone F (5.0 g, 9.55 mmol, 86.2% potency) and diphenylphosphoryl azide (2.27 ml, 10.5 mmol, 1.1 eq) in tetrahydrofuran (40 ml) was added gradually 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 1.71
15 ml, 11.46 mmol, 1.2 eq) and the reaction subsequently stirred at 25-40°C for 4-6 hrs. To the reaction mixture was then added a 6.0 M solution of ammonium acetate (7.96 ml, 47.7 mmol, 5 eq) followed by 1.0 M trimethylphosphine / tetrahydrofuran solution (1.5 eq). The reaction mixture was diluted with water and the aqueous phase extracted with three portions of
20 ethyl acetate (40 ml each). The organic phase was then washed with three portions of diluted ammonium hydroxide (40 ml each). The combined aqueous washes are then extracted with two portions of ethyl acetate (40 ml each). The combined ethyl acetate phases are washed with two portions of water (20 ml each) then concentrated and azeotropically dried under reduced
25 pressure to a final volume of 60 ml. The resulting solution was heated at 65-


75°C and 70 ml n-heptane was added slowly. The mixture was allowed to cool slowly and stirred at a final temperature of 15-20 °C. The resulting solid (3.34 g, 78 % corrected for input potency) was isolated by filtration followed by vacuum drying to afford crystalline product.

5

CLAIMS


We claim:

1. A method for the preparation of 21-amino epothilone derivatives of
 5 formula (I)




wherein R is selected from the group consisting of H, alkyl, or substituted alkyl; X is selected from the group consisting of a carbon-carbon bond, O, S, CH₂, or NR'; Y is O or NH; R' is selected from the 10 group consisting of H, alkyl, aryl, -CO-R'', -CO₂R''', CONHR'', CONR''R''', SO₂R''', SO₂NHR'', and SO₂NR''R'''; R'' and R''' are independently selected from the group consisting of alkyl, aryl, aryl-alkyl, heteroaryl, and heteroaryl-alkyl, or R'' and R''' taken together with the nitrogen to which they are attached may comprise a nitrogen 15 heterocycle; and wherein R'' may also be H; comprising the steps of

(a) contacting a 21-hydroxy epothilone derivative of formula (IV)



with an azido transfer agent to form a 21-azido epothilone of formula (V); and



(b) contacting the 21-azido epothilone with a reducing agent to form
5 a 21-amino epothilone derivative according to formula (I).

2. The method of claim 1 further comprising:

a) reacting an epothilone starting material with an oxidizing agent;

or

10 b) converting an epothilone starting material by biotransformation; to obtain a 21-hydroxy epothilone derivative according to formula (IV), then reacting the compound of formula (IV), *in situ*, with the azido transfer agent according to step (a) to form a compound of formula (V).

15

3. The method of claim 2 wherein the biotransformation is performed using a microorganism.

4. The method of claim 2 wherein the biotransformation is performed using an enzyme.

5. The method of claim 1 wherein the reducing agent is a palladium catalyst or an organophosphine reagent.
6. The method of claim 5, wherein the reducing agent is a trialkyl phosphine and the azido transfer agent is a dialkyl phosphoryl azide.
7. The method of claim 2 wherein the oxidizing agent is mCPBA.
8. The method of claim 1 wherein the reaction of step (a) is carried out in the presence of a non-nucleophilic base.
9. The method of claim 1 wherein the reaction of step (b) is carried out in the presence of a water, a base, a buffer, or combination thereof.
- 15 10. The method of claim 8 wherein the non-nucleophilic base is selected from the group consisting of 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]-undec-7-ene, 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), 2,4,6-tri-tert-butylpyrimidine and diisopropylethylamine.
- 20 11. The method of claim 9 wherein the base is selected from the group consisting of ammonium hydroxide, ammonium salts or water, and the buffer is selected from the group consisting of mixtures thereof.

12. The method of claim 1 further comprising removal of excess solvent to provide a dried product containing a 21-amino epothilone derivative according to formula (I).


5 13. The method of claim 12 further comprising purifying the 21-amino epothilone derivative by crystallization from an organic solvent.

14. The method of claim 12 further comprising purifying the 21-amino epothilone derivative by chromatography.

10

15. A method for the preparation of a 21-amino epothilone derivative comprising:

a) converting a compound of formula (II)




II

15 wherein R and X are as defined in claim 1, by:


- (i) reaction with an oxidizing agent, or
- (ii) biotransformation;

b) to form a 21-hydroxy epothilone derivative according to formula (IV);

20




c) reacting the compound of formula (IV) to form a 21-azido epothilone derivative according to formula (V); and



5

d) reacting the compound of formula (V) to form a 21-amino epothilone derivative according to formula (I)



16. The method of claim 15 wherein each of X and Y is O, and R is H or
10 methyl.

17. The method of claim 15 wherein the biotransformation of step (a) is
performed using microorganisms.

18. The method of claim 15 wherein the biotransformation of step (a) is performed using an enzyme.

19. The compound formed according to the method of claim 1.

5

20. The compound formed according to the method of claim 15.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 2003/070170 A3

(51) International Patent Classification⁷: C07D 277/04, 277/18, 277/20, 263/32, 203/26, 235/08, 413/06, 313/00

(74) Agents: BAXAM, Deanna et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(21) International Application Number:
PCT/US2003/004426

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 13 February 2003 (13.02.2003)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/357,554 15 February 2002 (15.02.2002) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
8 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/070170 A3

(54) Title: METHOD OF PREPARATION OF 21-AMINO EPOTHILONE DERIVATIVES

(57) Abstract: An improved method of synthesis of 21-amino epothilone derivatives which provides a one-pot conversion of 21-hydroxy epothilones to highly desirable 21-amino epothilones in high yield.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04426

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 277/04, 277/18, 277/20, 263/32, 203/26, 235/08, 413/06, 313/00
 US CL : 548/204, 305.1, 310.1, 180, 159, 217, 193, 184, 186, 132; 549/214, 271, 235, 236

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 548/204, 305.1, 310.1, 180, 159, 217, 193, 184, 186, 132; 549/214, 271, 235, 236

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|------------------------------------------------------------------------------------|-----------------------|
| A | US 6,291,684 B1 (Borzilleri et al) 18 September 2001 (18.09.2001), columns 2-3. | 1-20 |
| A | US 6,300,355 B1 (Danishefsky et al) 09 October 2001 (09.10.2001), columns 6-10. | 1-20 |
| A, P | US 6,387,927 B1 (Altmann et al) 14 May 2002 (14.05.2002), columns 2-4. | 1-20 |
| A, E | US 6,531,497 B1 (Nicolaou et al) 11 March 2003 (11.03.2003), columns 2-5. | 1-20 |
| A, E | US 6,589,968 B2 (Arslanian et al) 08 July 2003 (08.07.2003), columns 2-11. | 1-20 |

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

24 September 2003 (24.09.2003)

20 MAY 2004

Name and mailing address of the ISA/US

Authorized officer

Mail Stop PCT, Attn: ISA/US
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Deborah C Lambkin

Facsimile No. (703)305-3230

Telephone No. 703-308-1235